Assenagon Asset Management’s PMV Pharmaceuticals PMVP Stock Holding History

Assenagon Asset Management’s Portfolio PMVP Stock Details PMVP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$442K	Sell	330,003 -30,783	-9%	-$39.5K	﹤0.01%	1082
2026 Q1	$447K	Buy	360,786 +220,318	+157%	+$280K	﹤0.01%	1015
2025 Q4	$176K	Buy	140,468 +17,376	+14%	+$23.3K	﹤0.01%	1124
2025 Q3	$172K	Sell	123,092 -139,967	-53%	-$194K	﹤0.01%	1137
2025 Q2	$279K	Buy	263,059 +148,021	+129%	+$145K	﹤0.01%	1093
2025 Q1	$125K	Sell	115,038 -38,663	-25%	-$52.5K	﹤0.01%	1125
2024 Q4	$232K	Sell	153,701 -200,136	-57%	-$317K	﹤0.01%	1270
2024 Q3	$527K	Buy	353,837 +93,809	+36%	+$145K	﹤0.01%	1237
2024 Q2	$421K	Buy	260,028 +189,214	+267%	+$341K	﹤0.01%	1263
2024 Q1	$120K	Hold	70,814	–	–	﹤0.01%	1344
2023 Q4	$220K	Sell	70,814 -187,724	-73%	-$497K	﹤0.01%	1365
2023 Q3	$1.59M	Sell	258,538 -162,286	-39%	-$1.12M	﹤0.01%	935
2023 Q2	$2.63M	Hold	420,824	–	–	0.01%	676
2023 Q1	$2.01M	Sell	420,824 -20,479	-5%	-$144K	0.01%	833
2022 Q4	$3.84M	Sell	441,303 -22,043	-5%	-$235K	0.01%	602
2022 Q3	$5.51M	Sell	463,346 -166,193	-26%	-$2.4M	0.02%	466
2022 Q2	$8.97M	Sell	629,539 -8,525	-1%	-$124K	0.03%	392
2022 Q1	$13.3M	Buy	638,064 +532,980	+507%	+$9.4M	0.04%	303
2021 Q4	$2.43M	Buy	105,084 +48,124	+84%	+$1.16M	0.01%	750
2021 Q3	$1.7M	Sell	56,960 -107,526	-65%	-$3.43M	0.01%	750
2021 Q2	$5.62M	Buy	+164,486	New	+$5.49M	0.02%	459

Other funds holding PMVP

Walleye Capital New York $28B AUM 44.22% 1-Year Est. Return

AWM

Accurate Wealth Management Wesley Chapel, Florida $1.05B AUM 30.92% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

CIAM

Caitong International Asset Management Hong Kong $729M AUM 1,176.98% 1-Year Est. Return

Assenagon Asset Management's PMVP Position: Q2 2026 in Review

Assenagon Asset Management reduced its PMV Pharmaceuticals (PMVP) stake by 8.5% in Q2 2026, selling an estimated $39.5K and leaving 330,003 shares worth $442K. The position accounts for ﹤0.01% of the portfolio, ranked #1082.

Assenagon Asset Management first reported a position in PMVP in Q2 2021 and has held it in 21 quarters since. The position peaked at $13.3M in Q1 2022. 5 funds tracked by Wall St. Rank hold PMVP as of Q2 2026.

Assenagon Asset Management held 330,003 shares of PMV Pharmaceuticals worth $442K as of Q2 2026.
Assenagon Asset Management sold 30,783 PMV Pharmaceuticals shares in Q2 2026, an estimated $39.5K.
PMV Pharmaceuticals made up ﹤0.01% of Assenagon Asset Management's portfolio in Q2 2026, its #1082 holding.
Assenagon Asset Management first reported a position in PMV Pharmaceuticals in Q2 2021 and has held it in 21 quarters since.
Assenagon Asset Management's PMV Pharmaceuticals position peaked at $13.3M in Q1 2022.
5 funds tracked by Wall St. Rank held PMV Pharmaceuticals as of Q2 2026.

Based on Assenagon Asset Management's 13F filing for Q2 2026, filed 8 Jul 2026.